# US 2013/0295074 A1 · Pyridoxamine for the Treatment of Diabetic Kidney Disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0295074 A1
- Document ID: US20130295074A1
- Status: Published application
- Kind: A1
- Application number: 13/935,791
- Filed: 2013-07-05
- Published: 2013-11-07
- Earliest claimed: 2003-06-20
- Applicants: Nephrogenex, Inc.
- Inventors: Thorsten Degenhardt; Robert Schotzinger; J. Wesley Fox
- Web page: https://patentgrep.com/patent/US20130295074A1

## CPC

- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/4412: having oxo groups directly attached to the heterocyclic ring
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 13/12: of the kidneys
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides pharmaceutical compositions comprising dosage units of pyridoxamine, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, and methods for their use in limiting the progression of renal disease and/or diabetic complications in human diabetic patient.

## Claims

### Claim 1

A pharmaceutical composition comprising:
(a) a dosage unit of 50 mg to 500 mg of pyridoxamine, or a pharmaceutically acceptable salt thereof; and
(b) a pharmaceutically acceptable carrier.

### Claim 2

A pharmaceutical composition comprising:
(a) pyridoxamine, or a pharmaceutically acceptable salt thereof; and
(b) one or more compounds selected from the group consisting of angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, aldose reductase inhibitors, calcium blockers, diuretics, glycosaminoglycans, insulin, incretin mimetics, insulin sensitizers, statins, fibrates, glucose uptake inhibitors, sulfonylureas, superoxide dismutase (SOD) and SOD mimetics, thiamine pyrophosphate and prodrugs thereof, transketolase inhibitors, AGE inhibitors, and protein kinase C inhibitors.

### Claim 3 (depends on 2)

The pharmaceutical composition of claim 2 wherein the one or more compounds are selected from the group consisting of angiotensin converting enzyme inhibitors and angiotensin receptor blockers, or pharmaceutically acceptable salts thereof in a pharmaceutically acceptable carrier.

### Claim 4 (depends on 2)

The pharmaceutical composition of claim 2, wherein the one or more therapeutics comprises an angiotensin converting enzyme inhibitor.

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4, wherein the one or more therapeutics comprises an angiotensin receptor blocker.

### Claim 6

A method for limiting the progression of renal disease and/or diabetic complications in a human diabetic patient being treated with one or more therapeutics selected from the group consisting of antihypertensive medications and glycemic control agents, comprising administering to the human diabetic patient an amount of pyridoxamine, or a pharmaceutically acceptable salt thereof, effective to limit the progression of renal disease and/or diabetic complications in the diabetic human patient.

### Claim 7 (depends on 6)

The method of claim 6 wherein the human diabetic patient is being treated with one or more angiotensin converting enzyme inhibitors.

### Claim 8 (depends on 6)

The method of claim 6 wherein the human diabetic patient is being treated with one or more angiotensin receptor blockers.

### Claim 9 (depends on 7)

The method of claim 7 wherein the human diabetic patient has failed to respond adequately to angiotensin converting enzyme inhibitor therapy.

### Claim 10 (depends on 8)

The method of claim 8 wherein the human diabetic patient has failed to respond adequately to angiotensin receptor blocker therapy.

### Claim 11 (depends on 6)

The method of claim 6 wherein the human diabetic patient has a baseline serum creatinine concentration of greater than or equal to 1.3 mg/dL.

### Claim 12 (depends on 6)

The method of claim 6 wherein the human diabetic patient has a whole blood HbA1C level of greater than 6.5%.

### Claim 13 (depends on 6)

The method of claim 6 wherein the patient has elevated blood lipid levels.

### Claim 14 (depends on 6)

The method of claim 6 wherein the human diabetic patient has type II diabetes.

### Claim 15 (depends on 11)

The method of claim 11 wherein the human diabetic patient has type II diabetes

### Claim 16

A method for limiting the progression of renal disease and/or diabetic complications in a human diabetic patient comprising administering to a human diabetic patient with a baseline serum creatinine concentration of greater than or equal to 1.3 mg/dL an amount of pyridoxamine, or a pharmaceutically acceptable salt thereof, effective to limit the progression of renal disease and/or diabetic complications in the human diabetic patient.

### Claim 17

A method for limiting the progression of renal disease and/or diabetic complications in a human diabetic patient, comprising administering to a human diabetic patient with a whole blood HbA1C level of greater than 6.5% an amount of pyridoxamine, or a pharmaceutically acceptable salt thereof, effective to limit the progression of renal disease and/or diabetic complications in the human diabetic patient.
